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Introduction: The aims of this study were to assess the reliability of circulating cell-free DNA (cf-DNA) concentrations,
compared with C-reactive protein (CRP), procalcitonin (PCT) and eosinophil count, in the diagnosis of infections in patients
with systemic inflammatory response syndrome (SIRS) and their prognostic values in a cohort of critically ill patients.
Methods: We conducted a prospective cohort study in a medical-surgical intensive care unit of a university hospital.
Eosinophil count and concentrations of cf-DNA, CRP, and PCT were measured in patients who fulfilled SIRS criteria at
admission to the intensive care unit (ICU) and a second determination 24 hours later. DNA levels were determined by a
PCR method using primers for the human beta-haemoglobin gene.
Results: One hundred and sixty consecutive patients were included: 43 SIRS without sepsis and 117 with sepsis. Levels of
CRP and PCT, but not cf-DNA or eosinophil count, were significantly higher in patients with sepsis than in SIRS-no sepsis
group on days 1 and 2. PCT on day 1 achieves the best area under the curve (AUC) for sepsis diagnosis (0.87; 95%
confidence interval = 0.81-0.94). Levels of cf-DNA do not predict outcome and the accuracy of these biomarkers for
mortality prediction was lower than that shown by APACHE II score. PCT decreases significantly from day 1 to day 2 in
survivors in the entire cohort and in patients with sepsis without significant changes in the other biomarkers.
Conclusions: Our data do not support the clinical utility of cf-DNA measurement in critical care patients with SIRS. PCT is of
value especially for infection identification in patients with SIRS at admission to the ICU.Introduction
One of the most frequent problems in the ICU is actu-
ally differentiating the inflammatory response from an
infective process. Clinical and standard laboratory tests
are not very helpful because most critically ill patients
develop some degree of inflammatory response, whether
or not they have sepsis. Predicting the outcome of inten-
sive care patients is also of particular transcendence to* Correspondence: jgarnachom@gmail.com
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markers have been evaluated to predict mortality in crit-
ically ill patients, although none have proved entirely
useful. The majority of these biomarkers have also been
assessed as a marker of underlying infection in systemic
inflammatory response syndrome (SIRS).
C-reactive protein (CRP) and procalcitonin (PCT) are
currently the most frequently used biomarkers in clinical
practice [1]. PCT is considered to have a higher capacity
to diagnose sepsis than CRP [2-4]. Eosinopenia has also
been proposed as a marker that may help to differentiate
sepsis-related conditions from other causes of SIRS [5].
The usefulness of eosinopenia as predictor of outcome in
critically ill patients has also been reported [6]. Eosinopenia
is an interesting biomarker because the eosinophil counted Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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costs would therefore be negligible.
Circulating cell-free DNA (cf-DNA) has recently received
growing attention and has been studied in various chronic
and acute disorders [7-9]. cf-DNA fragments are small
acellular double-stranded molecules with a lower molecu-
lar weight than genomic DNA circulating in peripheral
blood. Although the origin of cf-DNA has not been com-
pletely elucidated, DNA fragments released by apoptotic
cells are considered the potential source of this type of
DNA [10]. High cf-DNA levels have been reported in
severe sepsis and cf-DNA has been proposed as a prog-
nostic marker in patients suffering from sepsis [11]. More-
over, in critically ill patients, infection is associated with
higher cf-DNA concentrations [12].
We set out to assess the performance of cf-DNA as a
potential biomarker to differentiate SIRS without infection
from sepsis. We compared cf-DNA with the two more
frequently used biomarkers (CRP and PCT) as well as with
the presence of eosinopenia. In addition, we analyzed the
reliability of these biomarkers to predict mortality in the
entire cohort and in the subgroup of patients with sepsis
compared with severity scales at admission.Methods
Setting
This prospective study was carried out in the ICU of the
Hospital Virgen del Rocío from July 2010 to June 2011.
This ICU is a 40-bed medico-surgical unit in a large uni-
versity hospital. The Institutional Review Board of the
Hospital Virgen del Rocio approved this protocol. Written
informed consent was obtained from the patient or the
next of kin before inclusion in this study.Study design
All adult patients meeting criteria for SIRS on admission
to the ICU were enrolled. The diagnosis of SIRS, severe
sepsis, and septic shock was established according to the
definitions of the American College of Chest Physicians
consensus conference [13]. All patients received stand-
ard supportive treatment following recommendations of
the Surviving Sepsis Campaign released in 2008 [14]. Pa-
tients with noncure malignancies [8] and acute myocardial
infarction [7] in the last month were excluded from this
study. The patients were classified as SIRS or sepsis by
two researchers unaware of the biomarker levels.
At ICU admission, severity of the illness was evaluated
by the Acute Physiology and Chronic Health Evaluation
(APACHE) II score, considering the worst data point for
the first 24 hours in the ICU [15]. Failure of organs and
severity of multiple organ dysfunction syndrome was
assessed by the Sequential Organ Failure Assessment
(SOFA) scale [16].The first blood sample was drawn into a lithium heparin
and ethylenediamine tetraacetic acid tube as soon as pos-
sible after the patient was admitted to the ICU and written
informed consent had been obtained. The second blood
sample was collected the following day, 24 hours after the
first sample. The serum fraction was separated by centri-
fugation at 1,000 × g for 5 minutes and these samples were
stored at −20°C. cf-DNA and PCT were measured in this
frozen fraction. In contrast, the eosinophil count and CRP
were determined at the moment of separation.
The white blood cell and eosinophil counts were mea-
sured by the Coulter hematology analyzer (Beckman
Coulter, Brea, CA, USA). The detection limit of the eosino-
phil count was 10 cells/mm3. CRP was measured by an
immunoturbidimetric assay on a Modularw P (Roche
Diagnostics, GmbH, Mannheim, Germany) chemistry
analyzer. The reference limit for this method is less than
0.5 mg/dl. PCT was measured by an immunofluorescent
assay using the BRAHMS PCT kit (Roche, Zurich,
Switzerland) following the manufacturer’s protocols. The
lower detection limit for this method is 0.05 ng/ml.
DNA from 400 μl serum samples was extracted with
the automatized ManNa Pure Compact Instrument
(Roche Diagnostics, Basel, Switzerland) using the Magna
Pure Compact Nucleic Acid Isolation Kit I, according to
the Total NA Plasma 100 400 V3 1 protocol. DNA is
eluted in a final volume of 50 μl and frozen at −20°C
until polymerase chain reaction (PCR) quantification.
Serum DNA was measured using a real-time quantita-
tive PCR assay for the β-globin gene. The quantitative
PCR analysis was performed using a Light-Cycler 480
Real-Time PCR instrument (Roche Diagnostics, Basel) by
the 5′ nuclease assay (Taqman assay). Two microliters
of DNA were amplified in a final volume of 20 μl using
the LC480 ProbesMaster Kit (Roche Diagnostics, Basel)
according to the manufacturer’s instructions. The β-globin
Taqman system consisted of the amplification primers β-
globin-354 F (5′-GTG CAC CTG ACT CCT GAG GAG
A-3′) and β-globin-455R (5′-CCT TGA TAC CAA CCT
GCC CAG-3′) and a dual-labeled fluorescent probe β-
globin-402 T (5′-(FAM) TCT GGC CAA GTT TCA ACT
CTG CTC GCT (TAMRA)-3′) at 95°C for 5 minutes and
at 62°C for 20 minutes for 48 cycles. The final size of
the amplicon was 102 base pairs. Results are expressed as
the genome equivalent (GE) per milliliter (1 GE = 6.6 pg
DNA). cf-DNA was also measured in 10 healthy adults
(control group).
Statistical analysis
Descriptive results of continuous variables were expressed
as the mean (standard error) or median (interquartile
range) depending of the normality of their distribution.
Comparisons between two independent continuous vari-
ables were analyzed by t test or Mann–Whitney U test. For
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an analysis of variance test was performed, followed by the
least significant difference test for post-hoc intragroup ana-
lysis. A chi-square test was carried out to compare
proportions.
Receiver operating characteristic curves and the respect-
ive areas under the curves (AUCs) were calculated for
APACHE II and SOFA scores and leukocyte, eosinophil,
CRP, cf-DNA and procalcitonin levels. Statistical compari-
sons of the AUC for each parameter were performed with
the DeLong test [17] by the MedCalc software 12.7.0 trial
version (MedCalc Software bvba, Belgium). The sensitiv-
ity, specificity, negative predicted value and positive pre-
dicted value were calculated based on the respective
cutoff values, which were determined using the Youden
index:
J ¼ max sensitivity þ specificity−1ð Þ
All statistical procedures were performed using SPSS
19.0 statistical software (SPSS, Chicago, IL, USA).
Results
A total of 163 patients fulfilling the inclusion criteria were
entered in this study. In all of these patients, a minimum
of two SIRS criteria was present at admission to the ICU.
Both researchers did not achieve agreement in three cases,
which were excluded. Sepsis was diagnosed in 117 patients
(44 with severe sepsis and 73 with septic shock) and 43
patients presented SIRS without infection (no-sepsis-
SIRS). In patients with no-sepsis-SIRS, all cultures were
negative.
The admission diagnoses of the 43 patients with SIRS but
without infection were acute respiratory failure (n = 13),
early postoperative course of abdominal surgery (n = 10),
congestive heart failure (n = 8), acute pancreatitis (n = 8),
multiple trauma (n = 2) and febrile syndrome in connective
tissue disease (n = 2).
In patients with sepsis, the most frequent sources of
infection were abdominal (n = 53) followed by the lung
(n = 25) and urologic (n = 14). Bacteremia was detected in
36/117 (30.8%) patients. Microbiological documentation
was achieved in 98/117 patients: Gram-negative infection
(n = 49), Gram-positive infection (n = 34), and polymicro-
bial infection (n = 15).
The mean time elapsed from ICU admission to blood
collection for the first determination of biomarkers was
6 hours without differences between patients with sepsis
and with no-sepsis-SIRS. The median cf-DNA concentra-
tion was 5,265 GE/ml (interquartile range 5,377 GE/ml)
on day 1 and 4,895 GE/ml (interquartile range 5,612.5
GE/ml) 24 hours later. The median cf-DNA level in
the control group was 283.5 GE/ml (interquartile range
208 GE/ml).Entire cohort
Diagnostic value
Levels of CRP and PCT on day 1 were significantly higher
in patients with sepsis than in the no-sepsis-SIRS group
(Table 1). This difference persisted on day 2. Conversely,
the eosinophil count and cf-DNA on days 1 and 2 did not
significantly differ in these two groups. The rate of eosino-
phil count below the detection breakpoint was higher in
patients without infection than in sepsis patients, although
this difference was not statistically significant (18/43
(42.9%) vs. 40/117 (34.2%); P = 0.317). Regarding sever-
ity scales, only the SOFA score was significantly higher
in sepsis patients than in patients with SIRS without
infection.
Table 2 summarizes the best cutoff values for the bio-
markers calculated using the Youden index and their
predictive accuracy for the specific diagnoses of SIRS
without infection and sepsis. The AUCs for all biomarkers
as predictors of sepsis are shown in Figure 1. On day 1,
PCT presents the best AUC (0.87 (0.81 to 0.94)), which is
significantly higher than the AUC for the rest of variables
(P < 0.01). The AUC of the receiver operating characteris-
tic curve for the diagnosis of sepsis versus SIRS for cf-
DNA is 0.60 (0.5 to 0.70). Performance of biomarkers
for infection detection was similar in medical patients
(n = 68) and in surgical patients (n = 92).
Prognostic value
ICU and hospital mortality rates were 28.1% (45 of 160)
and 35.6% (57 of 160), respectively. As shown in Table 1,
ICU and hospital mortality rates were not statistically
different in these two groups (sepsis vs. SIRS without
infection).
Comparison between survivors and nonsurvivors is
presented in Table 3. APACHE II and SOFA scores were
significantly higher in patients who died during hospital-
ization. The PCT level decreases significantly from day 1
to day 2 in survivors (6.98 ng/ml (31.44) vs. 4.06 ng/ml
(17.79); P < 0.001) but not in nonsurvivors without
changes in the other biomarkers. The cutoff values for
mortality prediction are CRP > 10.38 mg/dl, PCT >
1.03 ng/ml, cf-DNA > 6,030 GE/ml, and eosinophils < 5
cells/mm3. In this case, SOFA score on day 1 presents
the greatest AUC (0.69 (95% confidence interval, 0.61
to 0.78)), which is significantly better than the AUC for
the rest of the variables (P < 0.01).
Patients with sepsis
Prognostic value
Table 4 presents the comparison of survivors and non-
survivors in the 117 patients with sepsis. As occurred in
the entire cohort, APACHE II and SOFA scores in the
first 24 hours in the ICU were significantly higher in
patients who died. On day 1 and day 2, the CRP, PCT or
Table 1 Baseline characteristics of the inception cohort
Total cohort (n = 160) SIRS patients (n = 43) Sepsis patients (n = 117) P valuea
Demographic variables
Gender (female) 81 (50.6) 29 (67.4) 52 (44.4) 0.010
Age 63 (51 to 74) 63 (48 to 75) 63 (52 to 73) 0.846
Underlying disease
Diabetes 35 (21.9) 12 (27.9) 23 (19.7) 0.263
Cirrhosis 6 (3.8) 1 (2.3) 5 (4.3) 0.565
ESRD 12 (7.5) 2 (4.7) 10 (8.5) 0.407
Immunosuppression 20 (12.5) 16 (13.7) 4 (9.3) 0.458
Cancer 20 (12.5) 5 (11.6) 15 (12.8) 0.840
Chronic cardiac insufficiency 11 (6.9) 4 (9.3) 7 (6) 0.462
COPD 22 (13.8) 6 (14) 16 (13.7) 0.964
SIRS
Two SIRS criteria 41 (25.6) 12 (27.9) 29 (24.8) 0.036
Three SIRS criteria 57 (35.6) 21 (48.8) 36 (30.8)
Four SIRS criteria 62 (38.8) 10 (23.3) 52 (44.4)
Severity scores
APACHE II 17 (12 to 24) 16 (11 to 22) 17 (13 to 24) 0.057
SOFA 7 (4 to 11) 4 (1 to 9) 8 (5 to 11) <0.001
Worst SOFA 8 (5 to 13) 5 (2 to 9) 9 (6 to 13) <0.001
Laboratory parametersb
Leukocytes day 1 13,130 (10,185) 12,780 (8,690) 13,160 (11,280) 0.079
Leukocytes day 2 14,700 (8,650) 12,910 (8,260) 15,395 (7,903) 0.056
Eosinophils day 1 55.6 (11.2) 38.3 (10.6) 61.8 (14.7) 0.434
Eosinophils day 2 91.1 (15.6) 95.6 (19.8) 78 (21.1) 0.533
CRP day 1 26.56 (21.91) 19.5 (25.52) 28.39 (20.98) 0.002
CRP day 2 28.85 (19.66) 23.39 (27.21) 30.2 (19.17) 0.003
PCT day 1 7.81 (34.91) 0.73 (1.49) 13.57 (45.87) <0.001
PCT day 2 4.82 (20.56) 0.97 (2.58) 10.35 (25.62) <0.001
cf-DNA day 1 5,265 (5,377) 4,170 (4,590) 5,770 (5,420) 0.081
cf-DNA day 2 4,895 (5,612.5) 4,490 (5,390) 5,090 (5,785) 0.417
cf-DNA day 1, without ARFc 5,050 (5,130) 4,105 (4,502) 5,760 (5,240) 0.106
cf-DNA day 2, without ARFc 4,960 (5,410) 3,700 (5,210) 5,410 (5,482) 0.077
Outcomes
Length of stay on ICU 7.5 (4 to 14) 6 (3 to 14) 8 (4 to 15) 0.420
ICU mortality 45 (28.1) 13 (30.2) 32 (27.4) 0.719
Hospital mortality 57 (35.6) 16 (37.2) 41 (35) 0.800
Data presented as n (%) or median (interquartile range). APACHE, Acute Physiology and Chronic Health Evaluation; ARF, acute renal failure; cf-DNA, cell-free DNA;
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ESRD, end-stage renal disease; PCT, procalcitonin; SIRS, systemic inflammatory response
syndrome; SOFA, Sequential Organ Failure Assessment. aP values for comparisons between SIRS and septic groups. bFor comparison, nonparametric tests were
used. cARF defined as renal SOFA ≥3 (n = 34).
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survivors. The eosinophil count was higher in nonsurvi-
vors than in survivors, although this difference did not
achieve statistical significance (83.41 (35.83) vs. 50.13
(11.80); P = 0.055). PCT diminished significantly on day
2 in relation to basal levels only in survivors (13.5(45.26) vs. 8.34 (22.55); P < 0.001). The other biomarkers
did not significantly change in the two determinations.
The APACHE II score exhibits the best AUC as predictor
of in-hospital mortality in patients with sepsis (0.690
(0.594 to 0.801)), followed by the SOFA scale (0.630 (0.524
to 0.734)). Comparing patients with severe sepsis and
Table 2 Clinical performance of biomarkers in diagnosing sepsis
Leukocytes CRP PCT cf-DNA Eosinophils
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
Sensitivity (%) 64.96 78.26 90.60 93.91 91.38 81.03 79.31 67.24 64.96 54.87
Specificity (%) 34.88 32.56 40.48 30.95 67.44 67.44 30.23 39.53 28.57 42.50
PPV (%) 73.08 75.63 80.92 78.83 88.33 87.04 75.41 75.00 71.70 72.94
NPV (%) 26.79 35.90 60.71 65.00 74.36 56.86 35.14 30.91 22.64 25.00
cf-DNA, cell-free DNA; CRP, C-reactive protein; NPV, negative predictive value; PCT, procalcitonin; PPV, positive predictive value.
Cutoff values were determined using the Youden index: leukocytes > 11 × 109 cells/l, CRP > 10.38 mg/dl, PCT > 1.39 ng/ml, cf-DNA > 2,850 GE/ml, and
eosinophils <25 cells/mm3.
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higher in patients with septic shock both on days 1 and 2.
Discussion
Our results support the utility of PCT as a biomarker to
differentiate sepsis from SIRS without infection. Accuracy
of CRP is lower than for PCT, whereas the eosinophil
count and cf-DNA serum levels cannot be recommended
as indicators of infection in patients with SIRS. In
addition, the usefulness of these biomarkers to predict
in-hospital mortality is low although a decrease of the
PCT levels in the first 2 days foresees a lower mortality.
In clinical routine, the initial differential diagnosis
between SIRS and sepsis is sometimes difficult. Clinical
signs of infection are nonspecific and the identification of
the culprit pathogen is not available in the early hours.Figure 1 Receiver-operating characteristic curves in the total
cohort for various biomarker cutoff levels. Receiver-operating
characteristic curves in the total cohort for cutoff levels of leukocytes,
C-reactive protein (CRP), procalcitonin (PCT), cell-free DNA (cf-DNA)
and eosinophils and Sequential Organ Failure Assessment (SOFA) and
Acute Physiology and Chronic Health Evaluation (APACHE) II scores in
differentiating between the presence and absence of sepsis at admission.
Areas under the receiver-operating characteristic curves: leukocytes, 0.55
(95% confidence interval (CI), 0.45 to 0.64); CRP, 0.69 (95% CI, 0.59 to
0.79); PCT, 0.87 (95% CI, 0.81 to 0.94); cf-DNA, 0.51 (95% CI, 0.61 to 0.71);
eosinophils, 0.54 (95% CI, 0.44 to 0.65); SOFA score, 0.74 (95% CI, 0.64 to
0.83); and APACHE II score, 0.62 (95% CI, 0.51 to 0.73).Sepsis is associated with a strong acute-phase response
resulting in pronounced changes in the concentrations
of many plasma components. Apart from their values
in discriminating no-sepsis-SIRS from sepsis, several
biochemical indicators have been assessed regarding their
potential in predicting prognosis.
Regarding the diagnostic utility, PCT was the most
useful biomarker for the identification of sepsis. A very
recent meta-analysis that assessed the accuracy of PCT
as a diagnostic marker of sepsis confirmed its validity
and calculated an area under the ROC curve of 0.85
(95% confidence interval, 0.81 to 0.88) [18], very similar
to our value. It is also interesting to point out that the
cutoff values which separated patients with and without
sepsis varied greatly in the different studies. We calculated
this value as 1.39 ng/ml, very close to values reported in
recent series [19,20].
We have also evaluated PCT as a prognostic biomarker
in the cohort of critically ill patients and in the subgroup
of septic patients. As in previous studies [21-24], basal
PCT determination is not useful to predict mortality and
its prediction capacity is lower than the clinical scores
(APACHE II or SOFA). We observed a significant decrease
of PCT on day 2 with respect to day 1 in survivors that
does not occur in nonsurvivors. PCT accuracy for mortality
prediction seems to improve with serial measurements
[21,25,26]. In septic shock, PCT has been identified as
a reliable early prognostic marker in medical patients
but not in surgical patients [27].
In agreement with our findings, PCT has been recently
identified as a good diagnostic marker but not as a prog-
nostic marker in sepsis [28]. In our study, PCT is signifi-
cantly higher in septic shock than in severe sepsis.
Serum PCT increases with greater severity of sepsis and
organ dysfunction [29]. Furthermore, PCT is useful to
predict treatment response and as a tool to discontinue
antibiotics, a very noteworthy function not evaluated in
our research [30].
We observed that the PCT capacity for infection iden-
tification is significantly higher than for CRP. PCT is
generally considered a more reliable marker than CRP in
defining infection as a cause of SIRS [2,3], although other
authors concluded that both biomarkers have similar
Table 3 Univariate analysis comparing survivors and nonsurvivors in total cohort
Total cohort (n = 160) Survivors (n = 103) Deaths (n = 57) P value
Demographic variables
Gender (female) 81 (50.6) 58 (56.3) 23 (40.4) 0.053
Age 63 (51 to 74) 62 (51 to 73) 68 (52 to 75) 0.026
Underlying diseases
Diabetes 35 (21.9) 23 (22.3) 12 (21.1) 0.852
Cirrhosis 6 (3.8) 1 (1) 5 (8.8) 0.022
ESRD 12 (7.5) 7 (6.8) 5 (8.8) 0.756
Immunosuppression 20 (12.5) 11 (10.7) 9 (15.8) 0.349
Cancer 20 (12.5) 7 (6.8) 13 (22.8) 0.003
Chronic cardiac insufficiency 11 (6.9) 6 (5.8) 5 (8.8) 0.523
COPD 22 (13.8) 14 (13.6) 8 (14) 0.938
SIRS
Two SIRS criteria 41 (25.6) 28 (27.2) 13 (22.8) 0.055
Three SIRS criteria 57 (35.6) 42 (40.8) 15 (26.3)
four SIRS criteria 62 (38.8) 33 (32) 29 (50.9)
Severity scores
APACHE II 17 (12 to 24) 16 (12 to 20) 22 (15 to 27) <0.001
SOFA 7 (4 to 11) 6 (3 to 9) 9 (6 to 12) <0.001
Laboratory parametersa
Leukocytes day 1 13,130 (10,185) 13,100 (9,490) 13,160 (12,615) 0.846
Leukocytes day 2 14,700 (8,650) 13,640 (8,290) 17,265 (8,343) 0.014
Eosinophils day 1 55.6 (11.2) 48.34 (9.55) 68.92 (26.51) 0.061
Eosinophils day 2 91.1 (15.6) 81.56 (13.04) 110 (38.99) 0.777
CRP day 1 26.56 (21.91) 27.95 (21.45) 23.44 (22.67) 0.460
CRP day 2 28.85 (19.66) 28.14 (18.10) 31.31 (20.46) 0.377
PCT day 1 7.81 (34.91) 6.98 (31.44) 8.93 (40.28) 0.325
PCT day 2 4.82 (20.56) 4.06 (17.79) 6.69 (26.12) 0.058
cf-DNA day 1 5,265 (5,377) 5,060 (4,760) 6,290 (6,405) 0.730
cf-DNA day 2 4,375 (5,522) 4,480 (6,030) 5,460 (4,580) 0.287
cf-DNA day 1, without ARFb 5,050 (5,130) 5,055 (4,562) 5,580 (6,825) 0.812
cf-DNA day 2, without ARFb 4,960 (5,410) 4,980 (5,885) 4,570 (5,090) 0.899
Data presented as n (%) or median (interquartile range). APACHE, Acute Physiology and Chronic Health Evaluation; ARF, acute renal failure; cf-DNA, cell-free DNA;
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ESRD, end-stage renal disease; PCT, procalcitonin; SIRS, systemic inflammatory response
syndrome; SOFA, Sequential Organ Failure Assessment. aFor comparison, nonparametric tests were used. bARF defined as renal SOFA ≥3 (n = 34).
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other markers) differentiates severe sepsis from septic
shock [4]. The different kinetics of these two biomarkers
and methodological differences may explain these discrep-
ancies, at least in part.
Different studies have shown that a low eosinophil count
is strongly related to the presence of bacterial infections
and is associated with a poor prognosis [5,6]. Persistent
eosinopenia has also been identified as an independent
predictor of mortality in hospitalized patients with
bacteremia [33]. In a study that included 68 critically ill
patients, diagnosis accuracy of the eosinophil count forsepsis identification was similar to that of CRP or PCT
[20]. However, CRP was a better marker than eosinophil
count for the diagnosis of bacteremia in critically ill
patients [34]. Our results do not support the value of
the eosinophil count as a prognostic or diagnostic marker
at ICU admission.
Interest has recently developed in the use of cf-DNA
as a biomarker in critically ill patients. Little is known
about the ability of cf-DNA to differentiate sepsis from
other causes of SIRS. Maximum measured concentrations
of cf-DNA in the first 4 days in the ICU were significantly
higher in infected than in non-infected critically ill
Table 4 Univariate analysis comparing survivors and








Gender (female) 39 (51.3) 13 (31.7) 0.042
Age 63 (52 to 73) 66 (52 to 74) 0.301
Underlying diseases
Diabetes 14 (18.4) 9 (22) 0.647
Cirrhosis 1 (1.3) 4 (9.8) 0.050
ESRD 6 (7.9) 4 (9.8) 0.739
Immunosuppression 10 (13.2) 6 (14.6) 0.825
Cancer 4 (5.3) 11 (26.8) 0.001
Chronic cardiac
insufficiency
5 (6.6) 2 (4.9) 0.998
COPD 9 (11.8) 7 (17.1) 0.432
SIRS
Two SIRS criteria 21 (27.6) 8 (19.5) 0.027
Three SIRS criteria 28 (36.8) 8 (19.5)
Four SIRS criteria 27 (35.5) 25 (61)
Severity scores
APACHE II 16 (12 to 22) 22 (16 to 27) 0.001
SOFA 7 (4 to 11) 10 (6 to 13) 0.007
Laboratory parametersa










Eosinophils day 1 50.13 (11.80) 83.41 (35.83) 0.055
Eosinophils day 2 82.23 (14.65) 123.24 (52.62) 0.747
CRP day 1 30.41 (15.77) 23.32 (20.91) 0.101
CRP day 2 29.84 (18.36) 30.72 (20.11) 0.794
PCT day 1 13.50 (45.26) 15.07 (57.42)
PCT day 2 8.34 (22.55) 12.13 (40.47)
cf-DNA day 1 5,490 (5,080) 6,660 (7,745) 0.495
cf-DNA day 2 4,830 (6,135) 5,460 (5,400) 0.890
Source of infection
Surgical 40 (52.6) 29 (70.7) 0.058
Nosocomial 28 (36.8) 16 (39) 0.816
Respiratory 17 (22.4) 8 (19.5) 0.719
Urinary 12 (15.8) 2 (4.9) 0.134
Abdominal 35 (46.1) 18 (43.9) 0.824
Central nervous system 1 (1.3) 0 0.999
Soft tissues 5 (6.6) 4 (9.8) 0.718
Bacteriemic 22 (28.9) 14 (31.4) 0.561
Unknown 3 (3.9) 2 (4.9) 0.999
Others 3 (3.9) 7 (17.1) 0.032
Table 4 Univariate analysis comparing survivors and
nonsurvivors in the septic patient cohort (Continued)
Outcomes
Length of stay in ICU 8 (4 to 18) 6 (3 to 14) 0.089
Length of stay in hospital 26 (18 to 43) 12 (5 to 22) <0.001
Data presented as n (%) or median (interquartile range). APACHE, Acute
Physiology and Chronic Health Evaluation; ARF, acute renal failure; cf-DNA,
cell-free DNA; COPD, chronic obstructive pulmonary disease; CRP, C-reactive
protein; ESRD, end-stage renal disease; PCT, procalcitonin; SIRS, systemic
inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment.
aFor comparison, nonparametric tests were used.
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http://ccforum.com/content/18/3/R116patients [12]. In a heterogeneous cohort of 110 febrile
patients, concentrations of cf-DNA have a diagnostic
capability similar to PCT and higher than that of CRP.
Noteworthy is the high AUC of cf-DNA and PCT (0.99
and 0.95 respectively) reported in this study [35].
Moreover, several studies have found that intensive
care nonsurvivors present higher cf-DNA concentrations
than surviving intensive care patients [11,34-38]. Inter-
estingly, cf-DNA levels do not seem to correlate with
CRP or PCT in septic patients [11]. In a cohort of critic-
ally ill patients, the maximum measured concentration
of cf-DNA in the first 4 days in the ICU but not the
levels at admission correlates with mortality and consti-
tutes an independent predictor of in-hospital mortality
[12]. In patients with severe sepsis and septic shock, basal
cf-DNA has been identified as an independent predictor
of ICU mortality but not of hospital mortality [36].
Our results therefore do not support the prognostic use-
fulness or the discriminative ability of cf-DNA between
patients with sepsis or no-sepsis-SIRS – although we
excluded patients with a noncure cancer or acute myo-
cardial infarction, conditions that increase cf-DNA levels.
Moreover, because cf-DNA is eliminated by urine [39]
we excluded patients with renal failure at admission, but
the diagnostic or prognostic accuracy of cf-DNA did not
improve.
We admit also several limitations. Biomarkers were
measured only at admission and 24 hours later. Their
performance especially for mortality prediction may be
better if the biomarkers were measured daily, although
the economic burden would have been clearly greater.
The relatively low number of patients included in our
study impedes us in exploring the value of these bio-
markers in specific infections or in different types or
pathogen (i.e. Gram-negative infection). No differences
in cf-DNA levels among patients with Gram-positive,
Gram-negative, or fungal infections have been reported
recently [37]. On the other hand, PCT levels seem to
be significantly higher in patients with Gram-negative
bacteremia than in bloodstream infections caused by
Gram-positive bacteria or fungi [40]. This fact adds
uncertainty to the PCT cutoff level that could depend
at least in part on the type of pathogen.
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our results and previous studies regarding the value of
cf-DNA. Impaired renal and hepatic function may influ-
ence serum cf-DNA levels as cf-DNA crosses the kidney
barrier and is partially excreted in urine [39]. The inclu-
sion of patients with derangement of these systems may
therefore alter cf-DNA levels. cf-DNA can be measured in
serum or in plasma with similar performance [41,42]. We
chose serum levels [43] and we consider it very unlikely
that this issue could explain differences with studies that
determine plasma levels. Very recently, our group has
reported that severe traumatic brain injury is associated
with elevated serum cf-DNA levels and a decrease during
the first 24 hours predicts outcome [9].
Conclusions
To sum up, the diagnosis of sepsis continues to be a
challenge in many clinical situations. PCT at admission
to the ICU has a high discriminative power and is superior
to CRP or the eosinophil count. cf-DNA levels do not help
to identify underlying infections at admission to the ICU
of patients with SIRS. Biomarkers evaluated in this study
poorly predict outcome although a reduction during the
first 24 hours of PCT is associated with a better outcome.
Further studies are required to precisely determine the
clinical value of cf-DNA in critically ill patients, but our
results do not support the incorporation of cf-DNA
measurement into clinical practice.
Key messages
 PCT at admission to the ICU has a high
discriminative power of sepsis.
 A reduction of PCT during the first 24 hours is
associated with a better outcome.
 cf-DNA levels do not help to identify underlying
infections at admission to the ICU of patients
with SIRS.
 Biomarkers evaluated in this study poorly predict
outcome.
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